🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Calling all physicians, scientists, nurses, public health experts interested in cancer: register now for the inaugural Moores Cancer Center Oncology CME event! #Cancer #CancerResearch #oncology #CME UCSD Division of Regenerative Medicine Department of Pharmacology, UCSD UC San Diego Health UC San Diego Stein Institute for Research on Aging crcera.ucsd.edu/delivering-dis…

ARE YOU READY???? Let's go! Ride/run/walk/spin Over $15 million raised to date to fund 78 innovative research grants in all types of cancer. @PedalSD Sanford Burnham Prebys Rady Children's Hospital-San Diego Scripps Research UCSD Health Moores Cancer Center CRCERA La Jolla Institute support.curebound.org/give/356638/#!…

You can still support cancer research and donate to our Pharm team UCSD! Link to click: support.curebound.org/team/389221 Thank you! GutkindLab @PedalSD

Benjamin Heyman, MD, of UCSD Health Moores Cancer Center CRCERA, discusses future therapeutic directions in mantle cell lymphoma #lymsm ow.ly/Tsch50IFFx0

Join us on April 20 for the #LungCancerSeries webinar on Management of Patients with #ALK #Mutated #NSCLC. With Moderator Hatim Husain and panelists Sai-Hong Ignatius Ou and Joel W. Neal, MD, PhD Free registration visit: events.r20.constantcontact.com/register/event…

Thomas Kipps, MD, PhD, of UCSD Health Moores Cancer Center CRCERA discusses navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS #lymsm #leusm ow.ly/uj5M50IKQCY

Please see select Gastrointestinal Stromal Tumor (#GIST) #Sarcoma abstracts presented at ASCO #ASCO22 Conquer Cancer, the ASCO Foundation The ASCO Post by Steve Bialick, DO Sylvester Comprehensive Cancer Center Pawel Sobczuk Marie Skłodowska-Curie Actions Vall d’Hebron Institute of Oncology (VHIO) Inga-Marie Schaefer Dana-Farber Jason Sicklick UCSD Health Moores Cancer Center CRCERA

Sandip P. Patel, MD, of UCSD Health Moores Cancer Center CRCERA, discusses frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm ow.ly/6hOs50Jfl6f

HOLD THE DATE: September 9, 2022 33rd Annual Mahajani Symposium focusing on TUMOR DORMANCY. Amazing line up including Cyrus Ghajar Gomes Lab Lucia Borriello Dr. Filippo G. Giancotti Mikala Egeblad Jean-Francois Cote @alvarezlabhutch and Kay Yeung. Co-hosted by Salk Institute UCSD Health Moores Cancer Center CRCERA SBP Cancer Center

Benjamin Heyman, MD, of UCSD Health Moores Cancer Center CRCERA, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma #lymsm bit.ly/3tk0h5v

Thomas Kipps, MD, PhD, of UCSD Health Moores Cancer Center CRCERA, discusses navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS #lymsm #leusm ow.ly/uj5M50IKQCY

Sandip P. Patel, MD, of UCSD Health Moores Cancer Center CRCERA, frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm ow.ly/eesZ50Iz8bl

Jennifer M. Matro, MD, of UCSD Health Moores Cancer Center CRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm ow.ly/AXY750Iz8le

Sandip P. Patel, MD, of UCSD Health Moores Cancer Center CRCERA, frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm ow.ly/AnkP50JAx9x

Jennifer M. Matro, MD, of UCSD Health Moores Cancer Center CRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm ow.ly/g9t050JBBps

Sandip P. Patel, MD, of UCSD Health Moores Cancer Center CRCERA, discusses frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm ow.ly/Cp3s50JMN1W

Jennifer M. Matro, MD, of UCSD Health Moores Cancer Center CRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm ow.ly/s5Jb50JMNix

Blocking tumour protein FAK releases checkpoint brake making #ovariancancer susceptible to #immunotherapy. Image and research by Duygu Ozmadenci et al UC San Diego Health Moores Cancer Center UC San Diego OBGYN UCSD Health Moores Cancer Center CRCERA in PNASNews. Read more on bpod.mrc.ac.uk/archive/2022/7… with MRC Laboratory of Medical Sciences (LMS) and Ant Lewis

Rana R. McKay, MD, of UCSD Health Moores Cancer Center CRCERA, discusses key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer. #pcsm ow.ly/x1Mv50MbIXP